Busulfan

Generic Name
Busulfan
Brand Names
Busulfex, Myleran, Busulfan Fresenius Kabi
Drug Type
Small Molecule
Chemical Formula
C6H14O6S2
CAS Number
55-98-1
Unique Ingredient Identifier
G1LN9045DK
Background

Busulfan is a bifunctional alkylating agent, having a selective immunosuppressive effect on bone marrow. It is not a structural analog of the nitrogen mustards. It has been used in the palliative treatment of chronic myeloid leukemia (myeloid leukemia, chronic), but although symptomatic relief is provided, no permanent remission is brought about. According t...

Indication

For use in combination with cyclophosphamide as a conditioning regimen prior to allogeneic hematopoietic progenitor cell transplantation for chronic myelogenous (myeloid, myelocytic, granulocytic) leukemia (FDA has designated busulfan as an orphan drug for this use). It is also used as a component of pretransplant conditioning regimens in patients undergoing...

Associated Conditions
Chronic Myelogenous Leukemia (CML), Essential Thrombocythemia (ET), Polycythemia Vera (PV)
Associated Therapies
Conditioning regimens for allogeneic stem cell transplantation therapy

PTCy and Ruxolitinib GVHD Prophylaxis in Myelofibrosis

First Posted Date
2016-06-20
Last Posted Date
2019-04-04
Lead Sponsor
St. Petersburg State Pavlov Medical University
Target Recruit Count
20
Registration Number
NCT02806375
Locations
🇷🇺

First Pavlov State Medical University of St. Petersburg, Saint-Petersburg, Russian Federation

GVHD Prophylaxis With Post-transplantation Bendamustine in Refractory Leukemia

First Posted Date
2016-06-14
Last Posted Date
2020-11-23
Lead Sponsor
St. Petersburg State Pavlov Medical University
Target Recruit Count
27
Registration Number
NCT02799147
Locations
🇷🇺

First Pavlov State Medical University of St. Petersburg, Saint-Petersburg, Russian Federation

HLA-Mismatched Unrelated Donor Bone Marrow Transplantation With Post-Transplantation Cyclophosphamide

First Posted Date
2016-06-08
Last Posted Date
2020-12-02
Lead Sponsor
Center for International Blood and Marrow Transplant Research
Target Recruit Count
80
Registration Number
NCT02793544
Locations
🇺🇸

Memorial Sloan Kettering Cancer Center - Adults, New York, New York, United States

🇺🇸

Karmanos Cancer Institute, Detroit, Michigan, United States

🇺🇸

Virginia Commonwealth University Massey Cancer Center Bone Marrow Transplant Program, Richmond, Virginia, United States

and more 8 locations

Bone Marrow Transplantation vs Standard of Care in Patients With Severe Sickle Cell Disease (BMT CTN 1503)

First Posted Date
2016-05-09
Last Posted Date
2024-04-17
Lead Sponsor
Medical College of Wisconsin
Target Recruit Count
138
Registration Number
NCT02766465
Locations
🇺🇸

Dana Farber Cancer Institute/Brigham & Women's Hospital, Boston, Massachusetts, United States

🇺🇸

Boston University, Boston, Massachusetts, United States

🇺🇸

Dana Farber Cancer Institute/Massachusetts General Hospital, Boston, Massachusetts, United States

and more 32 locations

International Randomised Phase III Clinical Trial in Children With Acute Myeloid Leukaemia

First Posted Date
2016-03-31
Last Posted Date
2021-10-08
Lead Sponsor
University of Birmingham
Target Recruit Count
700
Registration Number
NCT02724163
Locations
🇦🇺

Monash Children's Hospital, Melbourne, Australia

🇦🇺

Women and Children's Hospital Adelaide, Adelaide, Australia

🇦🇺

Queensland Children's Hospital, Brisbane, Australia

and more 65 locations

Autologous Hematopoietic Stem Cell Transplantation as Adjuvant Treatment for Triple Negative Breast Cancer Patients

First Posted Date
2016-02-01
Last Posted Date
2020-01-14
Lead Sponsor
Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran
Target Recruit Count
20
Registration Number
NCT02670109
Locations
🇲🇽

Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, Mexico City, Distrito Federal, Mexico

© Copyright 2024. All Rights Reserved by MedPath